

# World Journal of *Clinical Cases*

*World J Clin Cases* 2023 April 16; 11(11): 2363-2581



## Contents

Thrice Monthly Volume 11 Number 11 April 16, 2023

## REVIEW

- 2363 Presbyphagia: Dysphagia in the elderly  
*Feng HY, Zhang PP, Wang XW*

## MINIREVIEWS

- 2374 Narrative minireview of the spatial epidemiology of substance use disorder in the United States: Who is at risk and where?  
*Cuadros DF, Branscum AJ, Moreno CM, MacKinnon NJ*
- 2386 Pyroptosis and its role in cancer  
*Liu SW, Song WJ, Ma GK, Wang H, Yang L*
- 2396 Platelet rich fibrin is not a barrier membrane! Or is it?  
*Agrawal AA*
- 2405 Advances in translational therapy for locally advanced gastric cancer  
*Zhao K, Na Y, Xu HM*

## ORIGINAL ARTICLE

## Retrospective Study

- 2412 Study of pathogenic genes in a pedigree with familial dilated cardiomyopathy  
*Zhang XR, Ren H, Yao F, Liu Y, Song CL*
- 2423 Classification of hepatobiliary scintigraphy patterns in segmented gallbladder according to anatomical discordance  
*Lee YC, Jung WS, Lee CH, Kim SH, Lee SO*
- 2435 Optimal laboratory testing protocol for patients with acne taking oral isotretinoin  
*Park YJ, Shin HY, Choi WK, Lee AY, Lee SH, Hong JS*

## Observational Study

- 2443 Etiology analysis for term newborns with severe hyperbilirubinemia in eastern Guangdong of China  
*Xu JX, Lin F, Wu YH, Chen ZK, Ma YB, Yang LY*

## CASE REPORT

- 2452 Aicardi-Goutières syndrome type 7 in a Chinese child: A case report  
*Lin SZ, Yang JJ, Xie TL, Li JY, Ma JQ, Wu S, Wang N, Wang YJ*

- 2457** Allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia and pulmonary eosinophilia: A case report  
*Zhang XX, Zhou R, Liu C, Yang J, Pan ZH, Wu CC, Li QY*
- 2464** Late presentation of dural tears: Two case reports and review of literature  
*Xu C, Dong RP, Cheng XL, Zhao JW*
- 2474** Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report  
*Qi JP, Jiang H, Wu T, Zhang Y, Huang W, Li YX, Wang J, Zhang J, Ying ZH*
- 2482** Anesthesia management in a pediatric patient with complicatedly difficult airway: A case report  
*Chen JX, Shi XL, Liang CS, Ma XG, Xu L*
- 2489** Intracranial large artery embolism due to carotid thrombosis caused by a neck massager: A case report  
*Pan J, Wang JW, Cai XF, Lu KF, Wang ZZ, Guo SY*
- 2496** Intraductal papillary mucinous neoplasm originating from a jejunal heterotopic pancreas: A case report  
*Huang JH, Guo W, Liu Z*
- 2502** Application of endoscopic retrograde cholangiopancreatography for treatment of obstructive jaundice after hepatoblastoma surgery: A case report  
*Shu J, Yang H, Yang J, Bian HQ, Wang X*
- 2510** Total removal of a large esophageal schwannoma by submucosal tunneling endoscopic resection: A case report and review of literature  
*Mu YZ, Zhang Q, Zhao J, Liu Y, Kong LW, Ding ZX*
- 2521** SMARCA4-deficient undifferentiated thoracic tumor: A case report  
*Kwon HJ, Jang MH*
- 2528** Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report  
*Zou Q, Shen RL, Guo X, Tang CY*
- 2535** Bilateral carpal tunnel syndrome and motor dysfunction caused by gout and type 2 diabetes: A case report  
*Zhang GF, Rong CM, Li W, Wei BL, Han MT, Han QL*
- 2541** Pregnancy complicated by juxtaglomerular cell tumor of the kidney: A case report  
*Fu X, Deng G, Wang K, Shao C, Xie LP*
- 2549** Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: Four case reports  
*Zhu Q, Gao BQ, Zhang JF, Shi LP, Zhang GQ*
- 2559** Successful treatment of breast metastasis from primary transverse colon cancer: A case report  
*Jiao X, Xing FZ, Zhai MM, Sun P*

- 2567** Different endodontic treatments induced root development of two nonvital immature teeth in the same patient: A case report  
*Chai R, Yang X, Zhang AS*
- 2576** Autoimmune encephalitis after surgery for appendiceal cancer: A case report  
*Mao YH, Li L, Wen LM, Qin JM, Yang YL, Wang L, Wang FR, Zhao YZ*

**ABOUT COVER**

Editorial Board Member of *World Journal of Clinical Cases*, Farooq Shahzad, FACS, MBBS, MS, Assistant Professor, Plastic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, United States. fooqs@hotmail.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

**INDEXING/ABSTRACTING**

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Hua-Ge Yin; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

**NAME OF JOURNAL**

*World Journal of Clinical Cases*

**ISSN**

ISSN 2307-8960 (online)

**LAUNCH DATE**

April 16, 2013

**FREQUENCY**

Thrice Monthly

**EDITORS-IN-CHIEF**

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

**PUBLICATION DATE**

April 16, 2023

**COPYRIGHT**

© 2023 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Advances in translational therapy for locally advanced gastric cancer

Kai Zhao, Ying Na, Hui-Min Xu

**Specialty type:** Oncology

**Provenance and peer review:**

Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B, B  
Grade C (Good): C, C, C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Kanaoujiya R, India;  
Kinami S, Japan; Preziosi F, Italy;  
Yuan X, China

**Received:** January 2, 2023

**Peer-review started:** January 2, 2023

**First decision:** January 20, 2023

**Revised:** February 2, 2023

**Accepted:** March 17, 2023

**Article in press:** March 17, 2023

**Published online:** April 16, 2023



**Kai Zhao, Ying Na, Hui-Min Xu**, Department of General Surgery, Weifang People's Hospital, Weifang 261041, Shandong Province, China

**Corresponding author:** Hui-Min Xu, MD, Chief Physician, Department of General Surgery, Weifang People's Hospital, No. 151 Guangwen Street, Kuiwen District, Weifang 261041, Shandong Province, China. [xhm001@126.com](mailto:xhm001@126.com)

### Abstract

Translational therapy refers to a combination of chemotherapy, radiotherapy, targeted therapy, and immunotherapy for patients with advanced gastric cancer who are initially unable to undergo R0 resection. This treatment can achieve partial or complete remission of the unresectable tumors to meet the criteria for R0 resection, thus enabling the patients to prolong their survival time and improve their quality of life. In gastric cancer, translational therapy has been tried and improved. At present, there are a large number of patients with locally advanced gastric cancer in China, and the selection of suitable patients for translational therapy to prolong objective survival and improve survival quality is one of the hot spots in the field of gastric cancer research.

**Key Words:** Translational therapy; Locally advanced; Gastric cancer; Chemotherapy; Radiotherapy treatment; Targeted therapy

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** In general, for patients with locally advanced gastric cancer, translational therapy can achieve different levels of survival benefit. Immunohistochemistry and genetic testing should be performed before treatment to select a more optimal comprehensive treatment strategy. For patients with locally advanced gastric cancer that is difficult to be resected at the initial stage, translational therapy followed by surgery can improve the survival benefit of patients.

**Citation:** Zhao K, Na Y, Xu HM. Advances in translational therapy for locally advanced gastric cancer. *World J Clin Cases* 2023; 11(11): 2405-2411

**URL:** <https://www.wjgnet.com/2307-8960/full/v11/i11/2405.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v11.i11.2405>



## INTRODUCTION

The incidence and mortality rates of gastric cancer are among the highest in China and around the world[1]. As early gastroenteroscopy is not performed in all medical centers, the proportion of patients with advanced gastric cancer is high, and locally advanced gastric cancer accounts for 10%-35%. R0 resection cannot be performed due to severe invasion by the tumor, which cannot be separated from surrounding normal tissues or may be wrapped around large vessels, metastasized to regional lymph nodes, and fused into clusters. Yoshida *et al*[2] proposed that advanced gastric cancer can be divided into four categories: Class I, metastases are technically resectable, including single liver metastases, and 16a2, b1 lymph node metastases; Class II, patients with resectable metastases, accompanied by multiple liver metastases, intrahepatic metastases larger than 5 cm, or accompanied by No. 16a1, b2, or mediastinal lymph node metastases; Class III is only peritoneal metastases visible to the naked eye; Class IV refers to the combination of other distant metastases in addition to peritoneal metastases[2]. Several national and international studies[3-5] have shown that D2 Lymph node dissection should be the first treatment option for advanced gastric cancer, and there is little difference between open surgery and laparoscopic surgery[6]. The treatment model has changed from a single D2 lymph node dissection to a multidisciplinary and comprehensive treatment based on surgery for patients with locally advanced cancer. The integrated treatment model can further improve the survival quality of patients compared to traditional radical surgery combined with postoperative chemotherapy. For patients with locally advanced cancer, attention is focused on the examination of comprehensive treatment options and reducing the proportion of perioperative recurrence and achieving partial or full remission of unresectable factors by translational therapy, which has become one of the hot spots of research. Based on existing national and international research results[7,8], the current translational therapy for locally advanced gastric cancer generally includes the following: postoperative adjuvant chemotherapy and chemoradiotherapy, targeted therapy and immunotherapy. Neoadjuvant therapy refers to the preoperative administration of chemotherapy or radiotherapy to lower tumor stage, increase R0 resection rate and pathological remission, and improve patient prognosis. Neoadjuvant chemotherapy has potential advantages such as elimination of small metastases and reduction of postoperative recurrence. Preoperative tumor vessels are more abundant, and the drug can enter the tumor *via* blood vessels more easily, which increases the sensitivity of radiotherapy. A series of studies have been conducted on preoperative neoadjuvant chemoradiotherapy[9].

## POSTOPERATIVE ADJUVANT CHEMOTHERAPY

The ACTS-GC study in Japan in 2011 included a total of 1059 patients with stage II and III gastric cancer after radical D2 surgery in a controlled study, with the experimental group ( $n = 529$ ) given S-1 monotherapy postoperatively and the control group ( $n = 530$ ) undergoing surgery only. The results showed that the 5-year progression-free survival (PFS) rate of patients in the experimental group (65.4% *vs* 53.1%, HR = 0.65, 95%CI: 0.54-0.80) was significantly higher, and the analysis showed that postoperative S-1 monotherapy provided benefit in patients with stage II and IIIA gastric cancer, but did not improve the survival of patients with stage IIIB disease[10]. Due to the difference in pharmacokinetics between Caucasians and Xanthoderms, and the fact that D0-D1 surgery for gastric cancer was mostly performed in Europe and America at that time, while D2 surgery was performed in Japan, the ACTS-GC study was not directly extended to the postoperative adjuvant treatment of gastric cancer in Europe and America. Furthermore, the JACCRO GC-07 study conducted in Japan treated advanced gastric cancer patients with either S-1 monotherapy or S-1 combined with docetaxel chemotherapy. The 3-year disease recurrence-free survival (RFS) rate (67.7% *vs* 57.4%,  $P = 0.0008$ ) and 3-year overall survival (OS) rate (77.7% *vs* 71.2%,  $P = 0.007$ ) were significantly improved in the combination treatment group[11]. In order to determine the optimal adjuvant treatment protocol for advanced gastric cancer, the CLASSIC study by Korean and Chinese researchers included 1035 patients with gastric cancer who underwent stage II-IIIb radical D2 surgery, and were randomly divided into the experimental group (520 cases) and the observational group (515 cases), and the experimental group was treated with the XELOX regimen (oxaliplatin and capecitabine) for 6 mo. The 5-year follow-up results showed that the XELOX regimen improved disease-free survival (DFS) (68% *vs* 53%,  $P < 0.0001$ ) and OS (78% *vs* 69%,  $P < 0.0015$ ), suggesting that the XELOX regimen can be used as the standard adjuvant chemotherapy regimen after D2 radical surgery for stage II-IIIb gastric cancer[12,13]. Based on the ACTS-GC and CLASSIC studies, it was determined that postoperative adjuvant chemotherapy may be the standard treatment strategy after radical D2 surgery for gastric cancer.

## POSTOPERATIVE ADJUVANT RADIOTHERAPY

As mentioned above, due to the different surgical protocols for gastric cancer used in Europe and America, postoperative chemotherapy is mostly combined with radiotherapy. A total of 559 patients

with T3-T4 stage surgically resectable gastric cancer were included in the study by Smalley *et al*<sup>[14]</sup> in 2012. These patients were randomly assigned to the surgery group or the surgery combined with postoperative radiotherapy group, and the results showed that patients in the surgery combined with postoperative radiotherapy group had a longer 3-year median RFS (27 mo *vs* 19 mo,  $P < 0.001$ ) and 3-year median OS (35 mo *vs* 27 mo,  $P = 0.0046$ ) than those in the surgery-only group<sup>[14]</sup>, which provided the basis for the subsequent NCCN gastric cancer guidelines. The ARTIST and ARTIST-II studies were conducted in Korea to determine whether the addition of radiotherapy to combination chemotherapy after radical surgery for D2 lymph node dissection improves patient survival<sup>[15,16]</sup>. The studies showed that the addition of radiotherapy to D2 Lymph node dissection plus two-drug adjuvant chemotherapy did not improve patient survival. According to the results of several randomized controlled studies in patients with locally advanced gastric cancer, combination chemotherapy after D2 radical surgery can improve patient survival. For patients with stage III gastric cancer after D2 radical surgery, two-drug combination is more effective than single-drug chemotherapy and the addition of radiotherapy to chemotherapy can improve the survival of patients with D0 or D1 lymph node dissection but cannot improve the survival of patients after D2 radical surgery.

Based on the results of a number of large randomized controlled studies (Table 1), for patients with locally advanced gastric cancer, adjuvant chemotherapy S-1, S-1 + docetaxel, SOX and XELOX are all optional chemotherapy regimens after radical D2 treatment which can significantly improve survival. For stage III gastric cancer patients after D2 radical resection, two-drug chemotherapy is more effective than single-drug chemotherapy. At present, all major guidelines recommend postoperative adjuvant therapy for locally advanced gastric cancer. Adding radiotherapy to postoperative chemotherapy could improve the survival rate of patients in the D1 or D0 clearance range, but could not further improve the survival rate of patients after D2 radical resection.

## TARGETED THERAPY

Progress is slow in targeted therapy research for gastric cancer, and overexpression of human epidermal growth factor receptor 2 (HER-2) may be an independent factor in the poor prognosis of gastric cancer. The T0GA study published in 2010 confirmed, for the first time, the effectiveness of trastuzumab in the treatment of advanced gastric cancer, opening the era of targeted therapy for advanced gastric cancer<sup>[17]</sup>. Currently, there are more drugs and studies targeting HER-2, vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR)-1, the hepatocyte growth factor (HGF)/tyrosine protein kinase Met (c-MET) signaling pathway, immune checkpoints and other related pathways and targets.

### Anti-HER-2-targeted drugs

HER-2 is a member of the epidermal growth factor family, which accelerates tumor cell growth and invasion by activating the RAS-RAF-MRK-MAPK pathway, PI3K-AKT and other pathways. The T0GA trial confirmed that trastuzumab combined with cisplatin-based chemotherapy can prolong OS in patients with locally advanced gastric cancer by approximately 1.2 mo<sup>[17]</sup>. The 2011 NCCN guidelines recommend first-line trastuzumab in combination with platinum-based chemotherapy for eligible patients with advanced gastric cancer, and clinical trials such as JFMC45-1102 showed that in patients with advanced gastric cancer who have not previously been treated with anti-HER2-directed agents, trastuzumab is beneficial as a second- or super-second-line agent<sup>[18]</sup>. Clinical trials such as HER-FLOT<sup>[19]</sup> have also shown that trastuzumab plays a role in the preoperative translational therapy and neoadjuvant therapy of locally advanced gastric cancer.

### Anti-angiogenesis-related targeted drugs

The VEGF family accelerates the formation of neovascularization in the tumor through a series of cellular pathways to provide sufficient blood supply and nutrition for tumor cells, and the current anti-angiogenesis-targeted drugs for locally advanced gastric cancer include monoclonal antibodies, tyrosine kinase inhibitors, *etc.* As monoclonal antibodies have more adverse effects and unsatisfactory clinical trial results, most of the drugs have not entered the clinic. Tyrosine kinase inhibitors mainly inhibit tumor angiogenesis by binding to the VEGFR and can selectively inhibit tyrosine kinase activity to exert anti-tumor effects. A phase II clinical trial of apatinib in locally advanced gastric cancer patients after failure of second-line chemotherapy showed that a single agent could improve the survival of patients with locally advanced gastric cancer who had previously received  $\geq 2$  failed chemotherapy regimens<sup>[20]</sup>. Currently, it is mainly used in China for third-line and above treatment of locally advanced gastric cancer or esophagogastric junction cancer.

### Anti-EGFR targeting drugs

The overexpression of EGFR in gastric cancer can reach 50%-63%, and its expression level is positively correlated with tumor aggressiveness and negatively correlated with differentiation degree and survival time, suggesting that EGFR may be a target in gastric cancer treatment. However, the clinical trial



**Table 1 Research on postoperative chemotherapy and radiochemotherapy for locally advanced gastric cancer**

Title of research study	Year	Country/district	Study design	Study assignment	Surgical procedure	Complete percentage	3-yr progression-free survival	Overall survival
ARTIST	2012	South Korea	Phase 3 randomized controlled study	Surgery + XP (228 cases); Surgery + XP + radiotherapy (230 cases)	D2	82%; 75%	74.2%; 78.2%	73%; 75%
INT-0116	2012	North America	Phase 3 randomized controlled study	Surgery (277 cases); R0 + radiotherapy/fluorouracil (282 cases)	D2	96%; 65%	-	-
CLASSIC	2014	Eastern Asia	Phase 3 randomized controlled study	Surgery (515 cases); Surgery + XELOX (520 cases)	D2	83%; 67%	59%; 74%	69%; 78%
RESOLVE	2021	China	Phase 3 randomized controlled study	Surgery + XELOX (364 cases); Surgery + SOX (364 cases); SOX + surgery + SOX\ S-1 (365 cases)	D2	70%; 68%; 58%	51.1%; 56.5%; 59.4%	-
ARTIST II	2021	South Korea	Phase 3 randomized controlled study	Surgery + S-1; Surgery + SOX (181 cases); Surgery + SOX + radiotherapy (183 cases)	D2	71%; 85%; 83%	64.8%; 74.3%; 72.8%	-
JACCROGC-07	2022	Japan	Phase 3 randomized controlled study	Surgery + S-1; Surgery + S-1 + docetaxel (456 cases)	D2	80%; 40%	57.4%; 67.7%	71.2%; 77.7%

results of related targeting drugs have not met the clinical application requirements.

### **Targeted drugs of the HGF/c-MET signaling pathway**

The HGF/c-MET signaling pathway is related to tumor cell migration, invasion and intra-tumor blood vessel formation. Also, 10%-15% of patients with advanced gastric cancer have amplification of MET, the gene encoding c-MET protein, and 30% of these patients have high expression of MET, and the expression level is negatively correlated with patient prognosis. However, the current clinical trial results of drugs targeting this pathway are unsatisfactory.

## **IMMUNOTHERAPY**

Immune checkpoint inhibitors are used to inhibit tumor growth and invasion by restoring the immune killing effect of host T cells on tumor cells and weakening the immune escape of tumor cells. KEYNOTE-059 is a global phase II clinical trial of programmed cell death protein (PD)-1 inhibitors for gastric cancer or esophagogastric junction cancer, which has shown that immunosuppressants are effective and safe in the treatment of advanced gastric cancer or esophagogastric junction cancer[21]. The CHECKMATE-649 study showed that chemotherapy combined with nivolumab significantly improved OS in patients with a PD-ligand 1 (PD-L1) combined positive score (CPS)  $\geq 5$  compared to chemotherapy alone, and that combination therapy resulted in a statistically significant benefit in PFS in patients with CPS  $\geq 1$  and in all randomized patients with CPS  $\geq 5$ [22]. Data analysis in the KEYNOTE-811 study of HER-2 positive patients showed that the experimental group (chemotherapy + trastuzumab + pembrolizumab) had a significantly improved objective remission rate (74.4% *vs* 51.9%  $P = 0.00006$ )[23]. The results of the ongoing ATTRACTION-05 study in Japan which is evaluating the efficacy and safety of adjuvant nivolumab in combination with SOX or XELOX regimens for stage III gastric or esophagogastric junction cancer after D2 radical surgery have not yet been published. The preliminary data of multiple phase II clinical trials of preoperative immunosuppressive agents combined with chemotherapy in the treatment of locally advanced gastric cancer presented at the 2021 ASCO Congress showed that the pathological complete response rate was 10%-30%[23-25]. At present, a number of multicenter, phase II, randomized controlled clinical trials of preoperative immunotherapy combined with neoadjuvant chemotherapy for the treatment of advanced gastric cancer (NICE study) are being conducted in China, and the results are expected to be announced.

## CONCLUSION

In translational therapy of locally advanced gastric cancer, D2 lymph node dissection is the first standard surgical procedure, and D2 radical surgery + a postoperative adjuvant chemotherapy regimen has long been used as the main treatment regimen. When there is a bottleneck in the therapeutic effect, the emergence of neoadjuvant chemotherapy has improved the survival quality of patients, thus establishing the use of neoadjuvant chemotherapy. D1 radical surgery + postoperative radiotherapy in Europe and America showed improved survival, but the later regimen of D2 radical surgery + postoperative adjuvant chemotherapy + radiotherapy has not further improved survival, and the therapeutic effect of neoadjuvant radiotherapy is still being verified. In recent years, microsatellite instability and high-frequency tumor mutation antigens in Epstein-Barr virus-positive gastric cancer are expected to be potential targets for gastric cancer immunotherapy, and there are several phase III clinical trials underway. We look forward to the announcement of the results. Targeted therapies for gastric cancer are progressing slowly, and the currently available drugs for different targets are not effective in the treatment of locally advanced gastric cancer, but the combination of immunotherapy with targeted therapies is also in progress[26]. Nivolumab in combination with ipilimumab and pembrolizumab plus trastuzumab[27] can improve the survival of patients to some extent, but the combination of drugs leads to an increase in adverse effects, and further comprehensive assessment of the benefit is thus needed.

### Challenges and opportunities

At present, with the continuous development of clinical research on translational therapy, its status in the treatment of locally advanced gastric cancer may be further improved, and immune and targeted therapies are also likely to make breakthroughs. Further refinement of treatment plans and models, identification of the best combination and treatment opportunities, and even the treatment sequence of immunotherapy and chemoradiotherapy are all future research directions. The heterogeneity of gastric cancer is strong, and the molecular characteristics of tumors are also important factors affecting treatment efficacy and prognosis of locally advanced gastric cancer. Future studies also need to be designed to stratify tumors more accurately. The author believes that with the rapid development of drug research and extensive clinical trials, the survival of patients with locally advanced gastric cancer is expected to be further improved.

## FOOTNOTES

**Author contributions:** Zhao K, Na Y, and Xu HM designed the study; Zhao K, Na Y, and Xu HM wrote the manuscript; all authors have read and approve the final manuscript.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest or financial interests with any organization involved in the research.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Kai Zhao 0000-0002-1773-4460; Ying Na 0000-0002-8356-9109; Hui-Min Xu 0000-0001-8896-571X.

**S-Editor:** Yan JP

**L-Editor:** A

**P-Editor:** Yan JP

## REFERENCES

- 1 Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. *Chin Med J (Engl)* 2021; **134**: 783-791 [PMID: 33734139 DOI: 10.1097/CM9.0000000000001474]
- 2 Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. *Gastric Cancer* 2016; **19**: 329-338 [PMID: 26643880 DOI: 10.1007/s10120-015-0575-z]
- 3 Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu

- Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. *Cancer Commun (Lond)* 2021; **41**: 747-795 [PMID: 34197702 DOI: 10.1002/cac2.12193]
- 4 **Japanese Gastric Cancer Association.** Japanese gastric cancer treatment guidelines 2018 (5th edition). *Gastric Cancer* 2021; **24**: 1-21 [PMID: 32060757 DOI: 10.1007/s10120-020-01042-y]
- 5 **Adachi Y,** Mori M, Maehara Y, Matsumata T, Okudaira Y, Sugimachi K. Surgical results of perforated gastric carcinoma: an analysis of 155 Japanese patients. *Am J Gastroenterol* 1997; **92**: 516-518 [PMID: 9068483]
- 6 **Huang C,** Liu H, Hu Y, Sun Y, Su X, Cao H, Hu J, Wang K, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Yu J, Zheng C, Liu F, Li Z, Zhao G, Zhang J, Chen P, Li G; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial. *JAMA Surg* 2022; **157**: 9-17 [PMID: 34668963 DOI: 10.1001/jamasurg.2021.5104]
- 7 **Sah BK,** Zhang B, Zhang H, Li J, Yuan F, Ma T, Shi M, Xu W, Zhu Z, Liu W, Yan C, Li C, Liu B, Yan M. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. *Nat Commun* 2020; **11**: 6093 [PMID: 33257672 DOI: 10.1038/s41467-020-19965-6]
- 8 **Satyananda V,** Gupta R, Hari DM, Yeh J, Chen KT. Advances in Translational Research and Clinical Care in Pancreatic Cancer: Where Are We Headed? *Gastroenterol Res Pract* 2019; **2019**: 7690528 [PMID: 30863442 DOI: 10.1155/2019/7690528]
- 9 **Yeoh KG,** Tan P. Mapping the genomic diaspora of gastric cancer. *Nat Rev Cancer* 2022; **22**: 71-84 [PMID: 34702982 DOI: 10.1038/s41568-021-00412-7]
- 10 **Sasako M,** Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. *J Clin Oncol* 2011; **29**: 4387-4393 [PMID: 22010012 DOI: 10.1200/JCO.2011.36.5908]
- 11 **Kakeji Y,** Yoshida K, Koda Y, Kochi M, Sano T, Ichikawa W, Lee SW, Shibahara K, Shikano T, Kataoka M, Ishiguro A, Ojima H, Sakai Y, Musha N, Takase T, Kimura T, Takeuchi M, Fujii M. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. *Gastric Cancer* 2022; **25**: 188-196 [PMID: 34351555 DOI: 10.1007/s10120-021-01224-2]
- 12 **Bang YJ,** Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. *Lancet* 2012; **379**: 315-321 [PMID: 22226517 DOI: 10.1016/S0140-6736(11)61873-4]
- 13 **Noh SH,** Park SR, Yang HK, Chung HC, Chung JJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JJ, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol* 2014; **15**: 1389-1396 [PMID: 25439693 DOI: 10.1016/S1470-2045(14)70473-5]
- 14 **Smalley SR,** Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. *J Clin Oncol* 2012; **30**: 2327-2333 [PMID: 22585691 DOI: 10.1200/JCO.2011.36.7136]
- 15 **Lee J,** Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. *J Clin Oncol* 2012; **30**: 268-273 [PMID: 22184384 DOI: 10.1200/JCO.2011.39.1953]
- 16 **Park SH,** Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, Kang JH, Oh SY, Hwang IG, Ji JH, Shin DB, Yu JI, Kim KM, An JY, Choi MG, Lee JH, Kim S, Hong JY, Park JO, Park YS, Lim HY, Bae JM, Kang WK; ARTIST 2 investigators. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial(☆). *Ann Oncol* 2021; **32**: 368-374 [PMID: 33278599 DOI: 10.1016/j.annonc.2020.11.017]
- 17 **Bang YJ,** Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschhoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; **376**: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
- 18 **Mitsui Y,** Sato Y, Miyamoto H, Fujino Y, Takaoka T, Miyoshi J, Kagawa M, Ohnuma H, Hirakawa M, Kubo T, Osuga T, Sagawa T, Takahashi Y, Katsuki S, Okuda T, Takimoto R, Kobune M, Nobuoka T, Hirata K, Kato J, Takayama T. Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy. *Cancer Chemother Pharmacol* 2015; **76**: 375-382 [PMID: 26099968 DOI: 10.1007/s00280-015-2807-7]
- 19 **Al-Batran SE,** Hozael W, Jäger E. Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases. *Onkologie* 2012; **35**: 505-508 [PMID: 23007148 DOI: 10.1159/000341841]
- 20 **Li J,** Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. *J Clin Oncol* 2013; **31**: 3219-3225 [PMID: 23918952 DOI: 10.1200/JCO.2013.48.8585]
- 21 **Shitara K,** Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The

- KEYNOTE-062 Phase 3 Randomized Clinical Trial. *JAMA Oncol* 2020; **6**: 1571-1580 [PMID: [32880601](#) DOI: [10.1001/jamaoncol.2020.3370](#)]
- 22 **Janjigian YY**, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet* 2021; **398**: 27-40 [PMID: [34102137](#) DOI: [10.1016/S0140-6736\(21\)00797-2](#)]
  - 23 **Janjigian YY**, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. *Nature* 2021; **600**: 727-730 [PMID: [34912120](#) DOI: [10.1038/s41586-021-04161-3](#)]
  - 24 **Bang YJ**, Van Cutsem E, Fuchs CS, Ohtsu A, Tabernero J, Ilson DH, Hyung WJ, Strong VE, Goetze TO, Yoshikawa T, Tang LH, Hwang PMT, Webb N, Adelberg D, Shitara K. KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. *Future Oncol* 2019; **15**: 943-952 [PMID: [30777447](#) DOI: [10.2217/fon-2018-0581](#)]
  - 25 **Rivera F**, Izquierdo-Manuel M, García-Alfonso P, Martínez de Castro E, Gallego J, Limón ML, Alsina M, López L, Galán M, Falcó E, Manzano JL, González E, Muñoz-Unceta N, López C, Aranda E, Fernández E, Jorge M, Jiménez-Fonseca P. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. *Eur J Cancer* 2021; **145**: 158-167 [PMID: [33485079](#) DOI: [10.1016/j.ejca.2020.12.005](#)]
  - 26 **Saito H**, Kuroda H, Matsunaga T, Osaki T, Ikeguchi M. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. *J Surg Oncol* 2013; **107**: 517-522 [PMID: [23129549](#) DOI: [10.1002/jso.23281](#)]
  - 27 **Janjigian YY**, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, Chou JF, Segal MF, Simmons MZ, Momtaz P, Shcherba M, Ku GY, Zervoudakis A, Won ES, Kelsen DP, Ilson DH, Nagy RJ, Lanman RB, Ptashkin RN, Donoghue MTA, Capanu M, Taylor BS, Solit DB, Schultz N, Hechtman JF. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. *Lancet Oncol* 2020; **21**: 821-831 [PMID: [32437664](#) DOI: [10.1016/S1470-2045\(20\)30169-8](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

